Lysine-Specific Demethylase 1 (LSD1) Is Required for the Transcriptional Repression of the Telomerase Reverse Transcriptase (hTERT) Gene

Qingjun Zhu1,2*, Cheng Liu1, Zheng Ge1, Xiaolei Fang2, Xi Zhang2, Klas Stråät1, Magnus Björkholm1, Dawei Xu1

1 Division of Hematology, Department of Medicine, Karolinska University Hospital Solna, Karolinska Institutet, Stockholm, Sweden, 2 College of Basic Medical Sciences, Shandong University of Traditional Chinese Medicine, Jinan, People’s Republic of China, 3 Institute of Urology, The Second Hospital, Shandong University, Jinan, People’s Republic of China, 4 Department of Obstetrics and Gynecology, Qilu Hospital, Shandong University, Jinan, People’s Republic of China

INTRODUCTION

The post-translational modification of nucleosomal histones, including acetylation, phosphorylation, methylation, ubiquitination and sumoylation, plays a key role in the regulation of gene transcription through remodelling chromatin structure [1]. Among all above modifications, regulated methylation of six known lysine (K) residues within the tails of histone H3 (H3-K4, H3-K9, H3-K27, H3-K36 and H3-K79) and H4 (H4-K20) is unique as mono- (M1), di- (M2) and tri- (M3) three modification states can be generated [2,3]. These different states, together with the identity of the modified lysine residues, result in diverse consequences on transcriptional activities. Methylation of H3-K4, H3-K9 and H3-79 is predominantly associated with transcriptionally active genes, whereas methylation of H3-K9, H3-K27 and H4-K20 marks silent genes or heterochromatin [1–3].

It is well known that histone acetylation and phosphorylation are dynamic and reversible, while histone methylation has long been thought as a static modification [1–3]. However, the recent discovery of multiple histone demethylases (HDMs) has totally changed this dogma, and thus the dynamic histone H3 methylation–mediated transcriptional regulation has emerged as a subject of intense investigations [2–5]. Lysine-specific demethylase 1 (LSD1), the first identified HDM [6], has attracted a great deal of interest because of its broad functional activities in transcriptional programs [7–15]. By interacting with diverse cofactors and catalyzing demethylation of mono- and di-methylated H3-K4 or K9, LSD1 is capable of either repressing or activating the target genes. For instance, when recruited to the target promoters by the androgen receptor, LSD1 removed the repressive H3-K9(M2) mark, thereby driving the androgen target activation [7,11–13]. On the other hand, LSD1 specifically demethylates H3-K4(M1) and (M2) that in turn leads to gene repression by maintaining a unmethylated H3-K4 status on its target promoters [6,8,13,16,17]. By eliciting such dual effects, LSD1 represses hTERT transcription via demethylating H3-K4 in normal and cancerous cells, and together with HDACs, participates in the establishment of a stable repression state of the hTERT gene in normal or differentiated malignant cells. The findings contribute to better understandings of hTERT/telomerase regulation, which may be implicated in the development of therapeutic strategies for telomerase dysregulation-associated human diseases including cancers.

Background. Lysine-specific demethylase 1 (LSD1), catalysing demethylation of mono- and di-methylated histone H3-K4 or K9, exhibits diverse transcriptional activities by mediating chromatin reconfiguration. The telomerase reverse transcriptase (hTERT) gene, encoding an essential component for telomerase activity that is involved in cellular immortalization and transformation, is silent in most normal human cells while activated in up to 90% of human cancers. It remains to be defined how exactly the transcriptional activation of the hTERT gene occurs during the oncogenic process.

Methodology/Principal Findings. In the present study, we determined the effect of LSD1 on hTERT transcription. In normal human fibroblasts with a tight hTERT repression, a pharmacological inhibition of LSD1 led to a weak hTERT expression, and a robust induction of hTERT mRNA was observed when LSD1 and histone deacetylases (HDACs) were both inhibited. Small interference RNA-mediated depletion of both LSD1 and CoREST, a co-repressor in HDAC-containing complexes, synergistically activated hTERT transcription. In cancer cells, inhibition of LSD1 activity or knocking-down of its expression led to significant increases in levels of hTERT mRNA and telomerase activity. Chromatin immunoprecipitation assay showed that LSD1 occupied the hTERT proximal promoter, and its depletion resulted in elevated di-methylation of histone H3-K4 accompanied by increased H3 acetylation locally in cancer cells. Moreover, during the differentiation of leukemic HL60 cells, the decreased hTERT expression was accompanied by the LSD1 recruitment to the hTERT promoter.

Conclusions/Significance. LSD1 represses hTERT transcription via demethylating H3-K4 in normal and cancerous cells, and together with HDACs, participates in the establishment of a stable repression state of the hTERT gene in normal or differentiated malignant cells. The findings contribute to better understandings of hTERT/telomerase regulation, which may be implicated in the development of therapeutic strategies for telomerase dysregulation-associated human diseases including cancers.

Citation: Zhu Q, Liu C, Ge Z, Fang X, Zhang X, et al (2008) Lysine-Specific Demethylase 1 (LSD1) Is Required for the Transcriptional Repression of the Telomerase Reverse Transcriptase (hTERT) Gene. PLoS ONE 3(1): e1446. doi:10.1371/journal.pone.0001446

Academic Editor: Christophe Herman, Baylor College of Medicine, United States of America

Received November 8, 2007; Accepted December 18, 2007; Published January 16, 2008

Copyright: © 2008 Zhu et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Funding: The study was supported by grants from The Swedish Cancer Society, the Cancer Society in Stockholm, the Swedish Research Council, Swedish Society of Medicine, Stockholm County Council and the Karolinska Institute Foundation (D Xu). The funders played no part in the work related to this manuscript.

Competing Interests: The authors have declared that no competing interests exist.

* To whom correspondence should be addressed. E-mail: Dawei.Xu@ki.se

† These authors contributed equally to this work.
LSD1 has been implicated in embryonic development, cell differentiation and proliferation, stem and cancer cell biology.

Telomerase, a RNA-dependent DNA polymerase silent in most normal human somatic cells, is frequently activated during the oncogenic process [18,19]. The compelling evidence suggests that activation of telomerase is essential for cellular immortalization and malignant transformation [18,19]. Moreover, telomerase and/or its components have also been implicated in the regulation of stem cell mobilization and proliferation [20,21]. It has been established that the stable repression of the telomerase catalytic subunit, encoded by the hTERT gene, is a predominant event resulting in the lack of telomerase activity in most normal cells [22–26]. Therefore, in order to acquire telomerase activity, it is necessary to erase negative regulators suppressing hTERT transcription. However, it remains incompletely understood how the repression or activation of the hTERT gene in normal and cancerous cells is achieved, despite great efforts in elucidating the underlying mechanisms during the past years.

Recent studies have started to uncover a close association between histone modifications including methylation and transcriptional activity of the hTERT gene in human cells [27–35]. Lack of histone H3-K4 methylation generally marks the repressive hTERT transcription in telomerase-deficient cells while the overexpression of SMYD3, a histone methyltransferase (HMT) that specifically di- and tri-methylates histone H3-K4, leads to the induction of hTERT mRNA expression via enhancing methylated H3-K4 at the hTERT proximal promoter region [34,35]. It has been shown that the transcription factor c-MYC, a key activator of the hTERT gene [36,37], is capable of binding to its target promoters only when the H3-K4 is methylated within appropriate regions of target promoters [38]. Conceivably, histone H3-K4 demethylation at the hTERT promoter may be required to lock the chromatin in a closed state in telomerase-deficient cells. However, it remains unknown which HDMs are associated with the hTERT promoter and responsible for maintaining H3-K4 demethylation locally. In the present study, we sought to address this issue by determining the potential role for LSD1 in controlling hTERT transcription.

**RESULTS**

Tranylcypromine treatment or depletion of LSD1 expression induces hTERT mRNA expression in MRC5 fibroblasts

The amino oxidase inhibitor tranylcypromine has been identified to potently suppress the enzymatic activity of LSD1 [17]. Therefore, to elucidate a potential role for LSD1 in the transcriptional regulation of the hTERT gene, we first incubated normal human MRC5 fibroblasts exhibiting a stable hTERT repression in the presence of tranylcypromine. As shown in Fig. 1A, hTERT transcripts were not observed in control MRC5 cells while tranylcypromine treatment induced a weak but detectable expression of hTERT mRNA. To rule out possible LSD1-independent, non-specific effects of tranylcypromine, we

---

Figure 1. The effect of LSD1 inhibition on the hTERT mRNA expression or gene transcription in human normal fibroblast MRC5 cells. (A) The induction and synergistic up-regulation of hTERT mRNA expression in MRC5 cells by the LSD1 inhibitor tranylcypromine alone and its combined treatment with the histone deacetylase (HDAC) inhibitor TSA, respectively. The cells were incubated with either tranylcypromine at 25.0 μM or TSA 0.1 μM, or both of them overnight and then harvested for hTERT mRNA analyses using RT-PCR. Trans: tranylcypromine. (B) The synergistic effect of LSD1 and CoREST depletion on the induction of hTERT mRNA in MRC5 cells. The knocking-down of LSD1 and CoREST expression was performed using the specific siRNA targeting LSD1 and CoREST. Arrow: primer dimmers. (C) The demonstration of efficient down-regulation of the target genes in siRNA-transfected cells. Lane 1: Control siRNA; lane 2: LSD1 (Upper) and CoREST siRNAs (Lower), respectively; and lane 3: LSD1+CoREST siRNAs. Note the results in (B) and (C) were from the same set of cDNA, and therefore, β2-M was only shown in (B). (D) The up-regulation of the hTERT promoter activity by tranylcypromine. The p181 reporter construct that harbors the hTERT proximal promoter sequence was transfected into MRC5 cells in the absence or presence of tranylcypromine, and then analysed for luciferase activity 48 hours later. Variation in transfection efficiency was normalized by the TK-driven Renilla luciferase activity. Columns: Relative luciferase activity arbitrarily expressed as the ratio of p181/TK Bars: SD. doi:10.1371/journal.pone.0001446.g001

---
knocked-down LSD1 expression by using the specific LSD1 siRNA. siRNA treatment of MRC5 cells resulted in silencing of LSD1 expression, and consistent with the finding described above, hTERT mRNA was induced in these LSD1-depleted cells (Fig. 1B). Taken together, both pharmacological inhibition of LSD1 activity and depletion of its expression are capable of de-repressing the hTERT transcription in normal human fibroblasts, although the effect was not robust.

The simultaneous inhibition of both LSD1 and HDACs is required for the optimal induction of hTERT mRNA expression in MRC5 cells

It has been previously shown that the inhibition of HDAC activity by TSA activates hTERT transcription in human fibroblasts and other cell types [27,28,31–33,39]. Moreover, an intimate interplay between LSD1 and HDACs has been observed [40]. We thus sought to probe whether a synergistic induction of hTERT expression could be achieved by inhibiting both LSD1 and HDAC activities. For this purpose, MRC5 cells were exposed to either tranylcypromine or TSA alone, or tranylcypromine plus TSA. A weak expression of hTERT mRNA was observed in cells treated with tranylcypromine at 25 μM or TSA at 0.1 μM, whereas the cell exposure to both tranylcypromine and TSA led to a robust increase in hTERT transcripts (Fig. 1A). The data suggest that LSD1 and HDACs cooperate to maintain a repressive state of the hTERT transcription in normal human MRC5 cells.

It is known that LSD1 interacts with CoREST, a co-repressor that exists in the HDAC-containing complex [8,16]. To corroborate the specific effect of tranylcypromine and TSA, we thus depleted both LSD1 and CoREST expression in MRC5 cells using a siRNA approach. The efficient knocking-down of these transcripts was verified with use of RT-PCR (Fig. 1C). The transfection of LSD1 but not CoREST siRNA into MRC5 cells induced minimal amounts of hTERT mRNA whereas the depletion of both of them synergistically activated hTERT transcription (Fig. 1B), which was in good accordance with the results achieved in MRC5 cells incubated with both tranylcypromine and TSA.

The hTERT promoter is activated in MRC5 cells in the presence of tranylcypromine

Next we sought to examine the effect of tranylcypromine on the hTERT promoter activity. p181, a reporter construct with an insert of the core hTERT promoter sequence [37], was transfected into MRC5 cells and luciferase activity driven by the hTERT core promoter was assessed 48 hours post-transfection in the presence or absence of tranylcypromine. As expected, the p181 activity in untreated MRC5 cells was very low, consistent with earlier observations. The exposure of the cells to tranylcypromine substantially increased the hTERT promoter activity in a dose-dependent manner (control vs tranylcypromine treatment at 10 and 100 μM, p<0.05, paired Wilcoxon two sample test) (Fig. 1D).

Tranylcypromine up-regulates hTERT expression and telomerase activity concomitant with elevated H3-K4(M2) and H3 acetylation at the hTERT proximal promoter in cancer cells

Having demonstrated an inhibitory role for LSD1 in the hTERT transcription in human normal fibroblasts, we wanted to further clarify its regulatory effect on hTERT expression in different cancer cells. The cervical cancer lines HeLa, SiHa and SW756, and a lung cancer line A549 cells were incubated with different concentrations of tranylcypromine overnight and were then analyzed for changes in hTERT mRNA and telomerase activity. The results documented in Fig. 2A showed a significant up-
The recruitment of LSD1 to the hTERT promoter accompanied by a loss of H3-K4(M2) and down-regulation of hTERT expression occur concomitantly during the terminal differentiation of leukemic HL60 cells

It has been well clarified that HL60 leukemic cells, when induced to undergo terminal differentiation, exhibit a stable repression of hTERT transcription [39,41–45]. To explore whether LSD1 is involved in the establishment of such a repressive state of the hTERT gene in the differentiated HL60 cells, we treated the cells with DMSO, a differentiation inducer, and then analysed binding of LSD1 to the hTERT proximal promoter. As expected, the DMSO exposure of HL60 cells triggered complete cessation of hTERT transcription within 48 hours (Fig. 4A). The ChIP results showed that LSD1 recruitment to the hTERT promoter did not occur in undifferentiated cells while it was readily observed in differentiated cells treated with DMSO for 48 hours, concomitant with the loss of H3-K4(M2) at the hTERT proximal promoter (Fig. 4B).

**DISCUSSION**

The methylated histone H3-K4 and K9 mark gene activation and repression, respectively [1–3]. LSD1, the first identified histone demethylase [6], has been shown to either repress a cohort of target genes through demethylation of H3-K4(M2) or activate other targets via removing the repressive mark H3-K9(M2), dependent on its interaction with different partners [6–8,12,17]. In the present study, we provide evidence that LSD1 is required for transcriptional repression of the hTERT gene in both normal and cancerous human cell lines.

Previous observations showed that the entire hTERT gene was embedded in a highly condensed chromatin in human normal fibroblasts with a tight repression of hTERT transcription [29,30]. When treated with a HDAC inhibitor, the local chromatin became open due to the increased histone acetylation, which thus allowed the transcriptional activation of the hTERT gene [22–26]. These data indicate an important role for HDAC-mediated histone deacetylation in repressing hTERT expression in telomerase-deficient cells. It is evident from the present investigation that LSD1 is similarly required for the establishment of repressive hTERT chromatin in normal fibroblasts. The activation of an optimal hTERT transcription can be achieved only when LSD1 and HDACs are both inhibited. Taken together, LSD1-mediated H3-K4 demethylation and HDAC-mediated histone deacetylation cooperate to establish a repressive transcriptional environment at the hTERT promoter region in human normal fibroblasts. Moreover, the recruitment of LSD1 to the hTERT promoter observed in differentiated HL60 cells provides independent evidence for its participation in the stable repression of the hTERT gene. It is currently unclear whether other histone demethylases are involved in the H3-K4 demethylation at the hTERT chromatin. This issue is now being addressed in our laboratory.

Intriguingly, the temporal patterns of expression of specific components of the LSD1 complex during the mammalian development cause a switch of LSD1 function from repression to activation, or reverse [13]. Therefore, we compared the transcriptional effect of LSD1 on the hTERT gene between cancer and normal cells. All the tested cancer cells including HeLa, SiHa, SW756 and A549 expressed hTERT mRNA and telomerase activity, but the pharmacological inhibition of LSD1 activity or depletion of its expression was capable of further up-regulating hTERT mRNA and telomerase activity levels, which clearly

**Depleting LSD1 expression induces higher levels of hTERT mRNA and telomerase activity via inhibiting H3-K4 demethylation at the hTERT proximal promoter in cervical cancer cells**

To obtain independent evidence for the inhibitory effect of LSD1 on hTERT transcription and telomerase activity, LSD1 expression was further knocked-down in HeLa and SiHa cells again using a siRNA strategy. As shown in Fig. 3A, LSD1 could be efficiently depleted in HeLa and SiHa cells. The up-regulation of hTERT mRNA and telomerase activity was observed in both cells, consistent with those documented in tranylcypromine-treated cells (Fig. 3A and B).

The depletion of LSD1 in HeLa and SiHa cells did not lead to global changes in the histone H3 methylation and acetylation profile (Fig. 3C). We then performed ChIP analyses to define potential alterations in H3 methylation associated with the hTERT proximal promoter in LSD1-depleted cells. The presence of LSD1 on the hTERT promoter was readily observed in the control cells while it became undetectable following LSD1-specific siRNA treatment (Fig. 3D). The depletion of LSD1 expression was accompanied by significant increases in H3-K4(M2) and histone H3 acetylation at the hTERT promoter in both HeLa and SiHa cells (Fig. 3D). There were no detectable histone H3-K9(M2) at the hTERT promoter region in either control or LSD1-depleted cells (Fig. 3D). These results provide evidence that LSD1 targets the hTERT gene and represses hTERT transcription via specifically demethylating histone H3-K4 (M2) at the hTERT proximal promoter in cervical cancer cell lines.
indicates an identical inhibitory effect of LSD1 on hTERT transcription in both normal and cancer cells. More importantly, the ChIP result demonstrated the LSD1 occupancy on the hTERT proximal promoter. Consistent with its functional activity, inhibition of LSD1 led to increased histone H3-K4 (M2) at the hTERT promoter region. In contrast, there were no detectable changes in H3-K9 methylation locally. It seems that LSD1 only targets H3-K4 for its demethylation at the hTERT promoter. Moreover, the LSD1-mediated H3-K4 demethylation was confined to the core promoter region without a further extension to upstream nucleosomes based on our unpublished data.

H3-K4 methylation alters the chromatin folding, leading to increased accessibility of DNA to proteins that mediate transcription [1–3]. It has been shown that the methylated H3-K4 is one of the prerequisites for the E-box binding by c-MYC on MYC target promoters [34,38]. Given the fact that hTERT gene is a direct target of c-MYC [36,37], the LSD1-mediated H3-K4 demethylation might prevent the c-MYC binding to the hTERT promoter, which in turn attenuates a transcriptional activity of the hTERT gene. Consistent with this hypothesis, we indeed observed that the depletion of LSD1 led to not only increased H3-K4(M2) but also H3-K4(M3) at the hTERT proximal promoter in HeLa cells (data...
implications in cancer and stem cell biology. telomerase silencing and activation in human cells, and have provide insights into the regulatory mechanism underlying human normal or differentiated malignant cells. Our findings thus the establishment of a stable repression state of the associated with the hTERT core promoter, LSD1 participates in demethylating H3-K4 and indirectly promoting H3 acetylation in cervical cancer cells treated with either LSD1 inhibitor or its specific siRNA. Taken together, LSD1 is capable of regulating the chromatin structure of the hTERT promoter region at multiple levels. Although LSD1 was observed to occupy the hTERT proximal promoter region, as demonstrated in our ChIP assay, it remains unclear how it is recruited there. We examined a potential interaction of LSD1 with the transcription factors Sp1 and MYC family members, the key regulators for hTERT transcription, and none of them were associated with LSD1 under our immunoprecipitation settings. It is thus plausible that LSD1 physically interacts with CoREST which is in the HDAC-containing complex [8,16], and thus it may further repress gene transcription program via indirectly promoting histone deacetylation. Consistently, we observed concomitant increases in histone H3-K4(M2) and H3 acetylation in cervical cancer cells treated with either LSD1 inhibitor or its specific siRNA. Taken together, LSD1 is capable of regulating the chromatin structure of the hTERT promoter region at multiple levels.

To conclude, the present study demonstrates that the histone demethylase LSD1 is required for the transcriptional repression of the hTERT gene in both normal and cancerous cells. By directly demethylating H3-K4 and indirectly promoting H3 acetylation associated with the hTERT core promoter, LSD1 participates in the establishment of a stable repression state of the hTERT gene in human normal or differentiated malignant cells. Our findings thus provide insights into the regulatory mechanism underlying telomerase silencing and activation in human cells, and have implications in cancer and stem cell biology.

MATERIALS AND METHODS

Cell lines, culture conditions, and chemicals
Human cervical cancer cell lines HeLa, SiHa and SW756, lung carcinoma cell line A549, normal fetal lung fibroblasts MRC5, and leukemic cell line HL60 were cultured at 37°C/95%air/5%CO2 in RPMI 1640 medium (Life Technologies, Paisley, Scotland, UK) containing 10% fetal calf serum, 100 units/ml penicillin, and 2 mM L-glutamine. The specific LSD1 inhibitor tranylcypromine and histone deacetylase (HDAC) inhibitor trichostatin A (TSA) were purchased from Biomol International LP (Plymouth Meeting, PA, USA) and Sigma-Aldrich Sweden AB (Stockholm, Sweden), respectively. HL60 cells were treated with 1.25% DMSO for 48 hours to induce their terminal differentiation [39].

siRNA treatment
Chemical modified Stealth™ siRNA targeting LSD1 and CoREST, and control siRNA were bought from Invitrogen (Carlsbad, CA, USA). The sequences for LSD1 and CoREST were UUU CCA UGA UAC CAG CAG CUU CUC C and AAG AUU GUC CCG UUC UUG ACU GCG U, respectively. MRC5 and cervical cancer cells were transfected with siRNA using Lipofectamine2000 (Invitrogen) according to the manufacturer’s protocol.

Total RNA extraction and RT-PCR
Total cellular RNA was extracted using ULTRASPEC™-II RNA kit (Biocentex, Houston, TX, USA). cDNA synthesis, the RT-PCR primers and conditions for hTERT mRNA were as described previously [46]. β2-M mRNA expression was used as a control for RNA loading and RT efficiency and was amplified with its specific primers for 26 cycles. PCR for both hTERT and β2-M mRNA was optimised to keep amplification in a linear phase, which allowed a semi-quantitative evaluation for the level of hTERT transcript as described [46]. The PCR primers for LSD1 mRNA are 5'-GAC TTC TTG GCA GAG TTG TC-3' (forward) and 5'-GTG AAA GAG TTG CAG ATC C-3' (reverse). RT-PCR for CoREST mRNA was carried out using the following primer pair: (forward) 5'-GGG ATG CTC TTC TGG CAT AA-3' and (reverse) 5'-GGA GGT TTC CTT TGG GTT CTA-3'.

Histone and total cellular protein extraction, and western blot
Preparation of a total histone fraction from nuclei was done by extraction with a dilute acid as described [33]. Total cellular proteins were extracted with RIPA lysis buffer. Two μg of histone proteins or 20 μg of total cellular proteins were resolved by sodium dodecyl sulfate-polyacrylamide gel electrophoresis and transferred to an intracellular membrane. The membranes were probed with the specific antibodies against methylated histone H3-K4(M1, M2 and M3), H3-K9(M1, M2 and M3), acetylated H3 or LSD1 (Upstate, NY, USA) followed by anti-mouse horseradish peroxidase-conjugated IgG and developed with the enhanced chemiluminescent method (ECL, Amersham, UK).

Telomerase activity assay
Telomerase PCR ELISA (Roche Diagnostics Scandinavia AB, Stockholm, Sweden) based on Telomeric Repeats Amplification Protocol was used to determine telomerase activity in all samples in duplicate according to manufacturer’s instruction [40]. One μg of protein from total cell lysates was added into the reaction mixture and the generated telomere product was PCR-amplified using 23 cycles. Four μl of products was used for ELISA assay and the level of telomerase activity was arbitrarily expressed as absorbance (OD450–OD690).

Luciferase activity assay
Transfection for luciferase activity assay was performed in 24-well plates using Lipofectamine2000 (Invitrogen). The hTERT lucif-
erase reporter (p181), kindly provided by Dr. S Kyo (Kanazawa University, Japan), harbors the core promoter sequence of the hTERT 5′-flanking region [37]. p181 was co-transfected with a Renilla reniformis luciferase-containing plasmid, which is under control of the thymidine kinase (TK) promoter. The transfected cells were then treated with different concentrations of transly- promine. Luciferase activity in the cell lysates was determined using a dual luciferase reporter assay system (Promega, WI, USA) 48 hrs post-transfection, and the hTERT promoter-driven firefly luciferase activity was normalized to the TK renilla activity.

**ChIP assay**

ChIP assay was done as described [33,34]. The HeLa, SiHa and H1.60 cells, under different treatment conditions, were cross-linked by incubating them in 1% (vol/vol) formaldehyde-containing medium for 10 mins at 37°C and then sonicated to make soluble chromatin with DNA fragments between 200 and 1000 bps. The antibodies against LSD1, H3-K4(M2), H3-K9(M2), and acetylated histone H3 (Upstate, NY, USA) were used to precipitate DNA fragments bound by their corresponding elements. The protein-DNA complex was collected with protein A or G Sepharose beads (Upstate), eluted, and reverse cross-linked. Following treatment with Protease K (Sigma), the samples were extracted with phenolchloroform and precipitated with ethanol. The recovered DNA was re-suspended in TE buffer and used for the PCR amplification as described [34]. The PCR primers for the proximal promoter regions (spanning between –296 and –22 relative to ATG) were 5′- CGG CCG CCG GCC GCT CCC AGT GGA T-3′ (forward) and 5′- GCC TTC CCA CGT GCG CAG CAG GA-3′ (reverse). The primers for GAPDH were described elsewhere [33].

**ACKNOWLEDGMENTS**

We thank Dr. S Kyo (Kanazawa University, Japan) for kindly providing plasmids.

**Author Contributions**

Conceived and designed the experiments: DX QZ CL. Performed the experiments: QZ CL ZG XF XZ KS. Analyzed the data: DX QZ CL ZG XF MB. Contributed reagents/materials/analysis tools: KS. Wrote the paper: DX MB.

**REFERENCES**

1. Berger SL (2007) The complex language of chromatin regulation during transcription. Nature 447: 407-12.
2. Ruthenburg AJ, Allis CD, Wysocka J (2007) Methylation of lysine 4 on histone H3: intricacy of writing and reading a single epigenetic mark. Mol Cell 25: 15-30.
3. Shi Y, Wohrten JL, Meissner A, Butte AJ, Rao VP (2007) Dynamic regulation of histone lysine methylation by degraspilases. Mol Cell 25: 1-14.
4. Klose RJ, Yan Q, Tothova Z, Yamane K, Erdjument-Bromage H, et al. (2007) The reintroinato for matabolism Protein RBP2 is an H3K4 demethylase. Cell 128: 89-99.
5. Christensen J, Agger K, Cloos PA, Pasini D, Rose S, et al. (2007) RBP2 belongs to a family of demethylases, specific for tri- and tetraacetyl lysine 4 on histone 3. Cell 128: 1063-76.
6. Shi Y, Lan F, Matson C, Mulligan P, Wohrten JL, et al. (2004) Histone demethylation mediated by the nuclear amine oxidase homolog LSD1. Cell 119: 941-53.
7. Metzger E, Wissmann M, Yin N, Muller JM, Schneider R, et al. (2005) LSD1 demethylates repressive histone marks to promote androgen-receptor-dependent transcription. Nature 437: 436-9.
8. Lee MG, Wynder C, Chu T, Shi Y, Dasilva KM, et al. (2005) Essential role for nonselective antidepressive compounds in neuronal gene expression. Nature 437: 436-9.
9. Shi YJ, Matson C, Lan F, Iwase S, Baba T, et al. (2005) Regulation of LSD1 demethylase by histone H3 lysine 4 demethylation is a target of nonselective antidepressive compounds. Nature 437: 432-5.
10. Huang Y, Greene E, Murray Stewart T, Goodwin AC, Baylin SB, et al. (2007) Inhibition of lysine-specific demethylase 1 by polyamine analogues results in repression of aberrantly silenced genes. Proc Natl Acad Sci U S A 104: 8023-8.
11. Hou M, Wang X, Popov N, Zhang A, Zhao X, et al. (2002) The histone deacetylase inhibitor trichostatin A derepresses the telomerase reverse transcriptase (hTERT) gene in human cells. Exp Cell Res 274: 25-34.
12. Cong Y, Batch S (2000) Histone deacetylation is involved in the transcriptional repression of hTERT in normal human cells. J Biol Chem 275: 33663-8.
13. Wang S, Zhu J (2003) Evidence for a relief of repression mechanism for activation of the human telomerase reverse transcriptase promoter. J Biol Chem 278: 18842-50.
14. Wang S, Zhu J (2004) The hTERT gene is embedded in a nuclease-resistant chromatin domain. J Biol Chem 279: 53401-10.
15. Takakura M, Kyo S, Sowa Y, Wang Z, Yatabe N, et al. (2001) Telomerase activity and causes proliferation of human telomerase negative cells. Cancer Res 61: 11341-7.
16. Wissmann M, Yin N, Muller JM, Greschik H, Fodor BD, et al. (2007) Cooperative demethylation by JMJ2C and LSD1 promotes androgen receptor-dependent gene expression. Nat Cell Biol 9: 547-53.
17. Wang S, Scully C, Zhu X, Cai L, Zhang J, et al. (2007) Opposing LSD1 complex formation in development of gene activation and repression programs. Nature 447: 802-7.
18. Wissmann M, Yin N, Muller JM, Schneider R, et al. (2007) Cooperative demethylation by JMJ2C and LSD1 promotes androgen receptor-dependent gene expression. Nat Cell Biol 9: 547-53.
19. Wang S, Xu J, Wang W, Zheng W, Sun J, et al. (2003) Telomere length on epidermal stem cell behavior. Science 309: 1253-6.
20. Sarin KY, Cheung P, Gilson D, Lee E, Tennen RI, et al. (2005) Conditional telomerase induction causes proliferation of hair follicle stem cells. Nature 436: 148-52.
21. Flores I, Gayuela ML, Blasco MA (2005) Effects of telomerase and telomere length on epidermal stem cell behavior. Science 309: 1253-6.
22. Cong YS, Wright WE, Shay JW (2002) Human telomerase and its regulation. Microbiol Mol Biol Rev 66: 407-25.
23. Horioka I, Barrett JC (2003) Transcriptional regulation of the telomerase hTERT gene as a target for cellular and viral oncogenic mechanisms. Carcinogenesis 24: 1167-76.
24. Kyo S, Inoue M (2002) Cooperative regulatory mechanisms of telomerase activity in normal and cancer cells: how can we apply them for cancer therapy? Oncogene 21: 688-97.
25. Liu JP (1999) Studies of the molecular mechanisms in the regulation of telomerase activity. Faseb J 13: 2091-104.
26. Lin SY, Elslager SJ (2003) Multiple tumor suppressor pathways negatively regulate telomerase. Cell 113: 881-9.
27. Hou M, Wang X, Popov N, Zhang A, Zhao X, et al. (2002) The histone deacetylase inhibitor trichostatin A derepresses the telomerase reverse transcriptase (hTERT) gene in human cells. Exp Cell Res 274: 25-34.
28. Cong YS, Batch S (2000) Histone deacetylation is involved in the transcriptional repression of hTERT in normal human cells. J Biol Chem 275: 33663-8.
29. Wang S, Zhu J (2003) Evidence for a relief of repression mechanism for activation of the human telomerase reverse transcriptase promoter. J Biol Chem 278: 18842-50.
30. Wang S, Zhu J (2004) The hTERT gene is embedded in a nuclease-resistant chromatin domain. J Biol Chem 279: 53401-10.
31. Takakura M, Kyo S, Sowa Y, Wang Z, Yatabe N, et al. (2001) Telomerase activation by histone deacetylase inhibitor in normal cells. Nucleic Acids Res 29: 3006-11.
32. Kumakura S, Tsumai TW, Yasuiwa J, Barrett JC, Tsutou T (2005) Reversible conversion of immortal human cells from telomerase-positive to telomerase-negative cells. Cancer Res 65: 2787-88.
33. Ge Z, Liu C, Bjorkholm M, Graher A, Xu D (2006) Mitogen-activated protein kinase cascade-mediated histone H3 phosphorylation is critical for telomerase reverse transcriptase expression/telomerase activation induced by proliferation. Mol Cell Biol 26: 230-7.
34. Liu C, Fang X, Ge Z, Jalink M, Kyo S, et al. (2007) The telomerase reverse transcriptase (hTERT) gene is a direct target of the histone methyltransferase SMD5. Cancer Res 67: 3620-31.
35. Atkinson SP, Hsiao SS, Glassford RM, Keith WN (2005) Lack of telomerase gene expression in alternative lengthening of telomeres is associated with chronic myelomonocytic leukemia. Cancer Res 65: 7505-10.
36. Horioka I, Cable PL, Aishari C, Barrett JC (1999) Cloning and characterization of the promoter region of human telomerase reverse transcriptase gene. Cancer Res 59: 826-30.
37. Takakura M, Kyo S, Kanaya T, Hirano H, Takeda J, et al. (1999) Cloning of human telomerase catalytic subunit (hTERT) gene promoter and identification of proximal core promoter sequences essential for transcriptional activation in immortalized and cancer cells. Cancer Res 59: 551-7.
38. Guccione E, Marinato F, Finocchiaro G, Luzzi L, Tizzoni L, et al. (2006) Myc-binding-site recognition in the human genome is determined by chromatin context. Nat Cell Biol 8: 764–70.

39. Xu D, Popov N, Hou M, Wang Q, Bjorkholm M, et al. (2001) Switch from Myc/Max to Mad1/Max binding and decrease in histone acetylation at the telomerase reverse transcriptase promoter during differentiation of HL60 cells. Proc Natl Acad Sci U S A 98: 3826–31.

40. Lee MG, Wynder C, Bochar DA, Hakimi MA, Cooch N, et al. (2006) Functional interplay between histone demethylase and deacetylase enzymes. Mol Cell Biol 26: 6395–402.

41. Albanell J, Han W, Mellado B, Gunawardane R, Scher HI, et al. (1996) Telomerase activity is repressed during differentiation of maturation-sensitive but not resistant human tumor cell lines. Cancer Res 56: 1503–8.

42. Sharma HW, Sokoloski JA, Perez JR, Maltese JY, Sartorelli AC, et al. (1995) Differentiation of immortal cells inhibits telomerase activity. Proc Natl Acad Sci U S A 92: 12343–6.

43. Zhang W, Piatyszek MA, Kobayashi T, Estey E, Andreeff M, et al. (1996) Telomerase activity in human acute myelogenous leukemia: inhibition of telomerase activity by differentiation-inducing agents. Clin Cancer Res 2: 790–803.

44. Xu D, Gruber A, Peterson C, Pisa P (1996) Suppression of telomerase activity in HL60 cells after treatment with differentiating agents. Leukemia 10: 1354–7.

45. Holt SE, Wright WE, Shay JW (1996) Regulation of telomerase activity in immortal cell lines. Mol Cell Biol 16: 2932–9.

46. Xu D, Gruber A, Peterson C, Pisa P (1996) Telomerase activity and the expression of telomerase components in acute myelogenous leukaemia. Br J Haematol 102: 1367–75.